H. Denison, C. Nilsson, L. Löfgren
Apr 1, 2014
Citations
2
Influential Citations
83
Citations
Quality indicators
Journal
Diabetes
Abstract
Inhibition of diacylglycerol acyltransferase 1 (DGAT1) is a potential treatment modality for patients with type 2 diabetes mellitus and obesity, based on preclinical data suggesting it is associated with insulin sensitization and weight loss. This randomized, placebo‐controlled, phase 1 study in 62 overweight or obese men explored the effects and tolerability of AZD7687, a reversible and selective DGAT1 inhibitor.